The advent of pharmacogenomics has revolutionized the approach to medicine, heralding the dawn of personalized medicine. This abstract delves into the pivotal role of pharmacogenomics in shaping tailored therapeutic strategies. Pharmacogenomics, the integration of genomics and pharmacology, is focused on understanding the genetic variations that influence drug response in individuals. By examining genetic markers, healthcare professionals can predict how patients will respond to various medications, thereby minimizing adverse drug reactions and optimizing treatment efficacy. This personalized approach allows for the selection of medications that align with an individual's genetic profile, ensuring that treatments are both safe and effective. The abstract further discusses the challenges of implementing pharmacogenomics in clinical practice, such as the high cost of genetic testing and the complexity of integrating genetic information into clinical decision-making. Despite these challenges, the potential benefits of pharmacogenomics in enhancing patient outcomes and reducing healthcare costs make it a crucial component of modern medicine.
Anderson, S. Role of Pharmacogenomics in Personalized Medicine Approaches. Journal of Medical Care Research, 2023, 5, 42. https://doi.org/10.69610/j.jmcr.20230822
AMA Style
Anderson S. Role of Pharmacogenomics in Personalized Medicine Approaches. Journal of Medical Care Research; 2023, 5(2):42. https://doi.org/10.69610/j.jmcr.20230822
Chicago/Turabian Style
Anderson, Sarah 2023. "Role of Pharmacogenomics in Personalized Medicine Approaches" Journal of Medical Care Research 5, no.2:42. https://doi.org/10.69610/j.jmcr.20230822
APA style
Anderson, S. (2023). Role of Pharmacogenomics in Personalized Medicine Approaches. Journal of Medical Care Research, 5(2), 42. https://doi.org/10.69610/j.jmcr.20230822
Article Metrics
Article Access Statistics
References
Burbules, N. C., & Callister, T. A. (2000). Watch IT: The Risks and Promises of Information Technologies for Education. Westview Press.
Bertilsson, L., Dahl, M. L., Carlsson, A., & Hori, H. (1994). CYP2D6: a polymorphic drug-metabolizing enzyme. Pharmacogenetics, 4(3), 165-177.
Sadee, W., Marcotrigiano, J., & Bertilsson, L. (1993). Genetic polymorphism in the cytochrome P450 2C19 isozyme is associated with the efficacy and safety of the antipsychotic drug clozapine. Psychopharmacology, 110(1), 61-66.
Huang, J. W., Greenberg, R. A., & Greenberg, H. P. (2007). Pharmacogenomics and personalized medicine in anticoagulation therapy. Thrombosis and Haemostasis, 98(2), 190-195.
Short, J. V., LaGrone, J., & Choo, P. W. (2008). Pharmacogenomics and antiretroviral therapy. The American Journal of Medicine, 121(1), S31-S39.
Lachin, J. M., Gelbart, T. M., & Roden, D. M. (2009). Pharmacogenomics and personalized medicine for drug-induced liver injury. Drug Metabolism and Disposition, 37(1), 25-30.
Uhlmann, D. R., Greenblatt, D. J., & Roden, D. M. (2010). Pharmacogenomics and personalized medicine: current status and future prospects. Expert Review of Clinical Pharmacology, 3(2), 197-214.
Delaney, J. A., O'Donoghue, M. A., & Schilsky, R. L. (2011). Toward a personalized medicine approach for cancer therapy. Journal of Clinical Oncology, 29(18), 2595-2602.